SCHEMBL8300975

SCHEMBL8300975

COC(=O)/C=C(/Nc1ccccc1OC)C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 1/20 0.52
KMT2A Q03164 4/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 3/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.51
MMP1 P03956 2/20 0.50
MMP2 P08253 2/20 0.50
MMP9 P14780 2/20 0.50
EGFR P00533 1/20 0.50
POLB P06746 2/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8293462 0.87 P2RX7 (0.45) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL8293661 0.86 LMNA (0.39) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL14392808 0.86 MAPT (0.41) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL8293470 0.86 JAK2 (0.41) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL13074498 0.86 ALDH1A1 (0.40) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL8293663 0.86 KMT2A (0.41) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL31563118 0.83 MAPT (0.45) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL14263886 0.82 HTT (0.44) SMN1; SMN2LMNAKMT2AALDH1A1MAPT
SCHEMBL14921880 0.82 RAB9A (0.50) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL15983169 0.81 ALDH1A1 (0.46) KMT2AALDH1A1MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939667-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 US disclosed
US-7939667-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 US disclosed
US-7585845-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-08 US disclosed
US-7585845-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-08 US disclosed
US-20070243166-A1 Hepatitis C Inhibitor Compounds LLINAS-BRUNET MONTSE 2007-10-18 US disclosed
US-20070243166-A1 Hepatitis C Inhibitor Compounds LLINAS-BRUNET MONTSE 2007-10-18 US disclosed
WO-2004103996-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070243166-A1 Hepatitis C Inhibitor Compounds HAVCR2, CTRL, CTRC SMN1; SMN2 4624/4885LMNA 816/4885KMT2A 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.